Израел - Хебрејски - Ministry of Health

sanofi israel ltd - hepatitis a vaccines - תרחיף להזרקה - hepatitis a vaccines 80 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - avaxim 80 u pediatric is indicated for active immunisation against infection caused by hepatitis a virus in children aged from 12 months to 15 years inclusive, who are at risk either of contaminating or spreading infection or of a life threatening disease if infected.

Израел - Хебрејски - Ministry of Health

glaxo smith kline (israel) ltd - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus; live attenuated varicella virus - אבקה וממס להכנת תמיסה להזרקה - live attenuated measles virus 10^ 3.0 ccid50; live attenuated mumps virus 10^ 4.4 ccid50; live attenuated rubella virus 10^ 3.0 ccid50; live attenuated varicella virus 10^ 3.3 pfu - measles, combinations with mumps, rubella and varicella, live attenuated - measles, combinations with mumps, rubella and varicella, live attenuated - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella in children from the age of 12 months up and including 12 years of age.

Израел - Хебрејски - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . adacel polio is not indicatd for primary immunisation. adacel polio is not indicated for treating diseases caused by b. pertussis, c.diphtheriae or c. tetani or by poliomyelitis infections.

Израел - Хебрејски - Ministry of Health

sanofi israel ltd - yellow fever virus strain 17d204 (substrain ab237) - אבקה וממס להכנת תרחיף להזרקה - yellow fever virus strain 17d204 (substrain ab237) - yellow fever, live attenuated

Израел - Хебрејски - Ministry of Health

glaxo smith kline (israel) ltd - poliomyelitis virus type 1; poliomyelitis virus type 1; poliomyelitis virus type 3 - תרחיף - poliomyelitis virus type 3 nlt 10^6.0 ccid50; poliomyelitis virus type 1 nlt 10^5.8 ccid50; poliomyelitis virus type 1 nlt 10^6.0 ccid50 - poliomyelitis oral, monovalent live attenuated

Израел - Хебрејски - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - measles virus enders edmonston strain (live, attenuated); mumps virus jeryl lynn™ (level b) strain (live, attenuated); rubella virus wistar ra 27/3 strain (live, attenuated); varicella virus oka/merck strain (live, attenuated) - אבקה וממס להכנת תרחיף להזרקה - measles virus enders edmonston strain (live, attenuated); varicella virus oka/merck strain (live, attenuated); rubella virus wistar ra 27/3 strain (live, attenuated); mumps virus jeryl lynn™ (level b) strain (live, attenuated) - measles, combinations with mumps, rubella and varicella, live attenuated

Израел - Хебрејски - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hpv type 11 l1 protein; hpv type 16 l1 protein; hpv type 18 l1 protein; hpv type 31 l1 protein; hpv type 33 l1 protein; hpv type 45 l1 protein; hpv type 52 l1 protein; hpv type 58 l1 protein; hpv type 6 l1 protein - תרחיף להזרקה - hpv type 58 l1 protein 20 mcg / 0.5 ml; hpv type 52 l1 protein 20 mcg / 0.5 ml; hpv type 45 l1 protein 20 mcg / 0.5 ml; hpv type 33 l1 protein 20 mcg / 0.5 ml; hpv type 31 l1 protein 20 mcg / 0.5 ml; hpv type 18 l1 protein 40 mcg / 0.5 ml; hpv type 16 l1 protein 60 mcg / 0.5 ml; hpv type 11 l1 protein 40 mcg / 0.5 ml; hpv type 6 l1 protein 30 mcg / 0.5 ml - papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)

Израел - Хебрејски - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - תמיסה להזרקה - human hepatitis b immunoglobulin 500 iu - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b virus (hbv) re-infection in hbv-dna negative patients ?6 months after liver transplantation for hepatitis b induced liver failure.zutectra is indicated in adults only.the concomitant use of adequate virostatic agents should be considered, if appropriate, as standard of hepatitis b re-infection prophylaxis.

Израел - Хебрејски - Ministry of Health

j-c health care ltd - etravirine - טבליה - etravirine 100 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti) - containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Израел - Хебрејски - Ministry of Health

j-c health care ltd - etravirine - טבליה - etravirine 200 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti)- containing regimen intelence is not recommended for use in combination with n(t)rtis only.